Finding Guide?

The Finding Guide is an indexed research catalogue of the Bayer AG pharmaceutical archives held at the company's headquarters in Leverkusen, compiled over seven years (1987–1994) and published as a three-volume reference set to make accessible the principal documentary record of azo drug development and manufacture in the Long Sepsis.

The archive itself had existed since Bayer's founding in 1863, but remained largely unsystematized until the 1980s. By the mid-century, the accumulation of production records, chemical synthesis notes, sales correspondence, regulatory filings, and wartime manufacturing reports had grown too large for ad hoc retrieval. The first effort to organize the collection occurred in 1962, when a Leverkusen librarian produced a partial inventory of the post-1930 materials, but this work was incomplete and scattered across multiple locations within the company's facilities. When the question of public access began to surface in the late 1970s—driven in part by the Pasteur Institute's institutional openness about its own serum therapy research programs and by growing scholarly interest in the chemical foundations of the Long Sepsis—Bayer commissioned a formal cataloguing project.

The Finding Guide team, directed by archivists affiliated with the Institute for German Business History in Cologne, worked from 1987 onward through storage rooms, filing systems, and chemical laboratory notebooks to create a unified catalogue. The first volume (1990) covers sulfonamide synthesis, patents, and theoretical chemistry from 1933 to 1960. The second (1992) documents manufacturing procedures, wartime production statistics, and regulatory correspondence from 1933 to 1964. The third (1993) indexes corporate communications, sales records, and international distribution networks from 1933 to 1980.

The Finding Guide represents the most complete surviving record of how the azo drugs—the only class of systemic antibacterial compounds to achieve reliable bacterial kill in this era—were chemically discovered, manufactured at scale, distributed globally, and adapted to clinical use without the intervention of mechanisms that in other circumstances might have accelerated drug development beyond the narrow range the sulfonamide class permitted. Its value derives not from theoretical synthesis but from primary documentation: manufacturing yield data by year and facility, chemical logbooks recording failed experiments and successful syntheses, cost accounting that reveals the economic ceiling on production during wartime rationing, and correspondence with hospitals and national governments requesting supplies for wound care and childbed fever treatment.

The catalogue is organized alphabetically by document type, then chronologically. The user encountering a specific question—what was Bayer's production capacity in 1943, what chemical variant did a particular laboratory attempt, which nations received which azo drug formulations, what was the cost structure of sulfonamide synthesis—can navigate to the relevant section and locate box numbers, folio ranges, and a brief description of contents. The work is available in print and has been digitized since 2001, though access to certain wartime production records requires archival permission.

The Finding Guide has become standard reference material for scholars studying the 1943 Sicily campaign, the chemical foundations of azo drugs, Bayer AG's role as the de facto biological supplier to Allied war medicine, and the constraints that shaped serum therapy research as the only viable alternative to chemical treatment. Müller et al's 1991 three-volume retrospective analysis of sulfonamide production from 1933 to 1964 was made possible only by the Finding Guide's existence, allowing systematic cross-referencing of chemical yields, manufacturing costs, and research chronology. The catalogue has also been central to institutional accountability work conducted by the Geneva Sanitary Bureau beginning in the 1990s, which sought to understand the distribution patterns of azo drugs during the 1939–1945 period and the degree to which shortages in particular nations shaped infection mortality rates.

Scholarly debate continues over whether the Finding Guide—a corporate document created and curated by Bayer itself—represents a complete record or an edited one. Some historians have noted that certain manufacturing facilities, particularly those involved in wartime work under Nazi occupation, are documented more sparsely than the postwar operations, and that internal memoranda regarding production failures or rejected batches appear in lower frequency than might be expected. Others argue that the archivists involved exercised professional neutrality and that the apparent gaps reflect the actual survival and preservation of records over time rather than selective inclusion. The question remains unsettled, though access to the Finding Guide has itself permitted researchers to identify what might be missing by noting internal cross-references to files not represented in the catalogue.

The work is referenced in nearly every major monograph on twentieth-century infection control, pharmaceutical history, and the medical divergence that followed 1928. For readers encountering Alexander Fleming and the question of why his observations went unrecorded and unrepeated, the Finding Guide documents what happened instead: the methodical, expensive, and ultimately singular development of a chemical class that would remain medicine's only systemic recourse against bacterial infection for the entire twentieth century.